TABLE 4.

Correlation of NOTCH1 and SF3B1 mutations with genomic change components to assess the prognostic status of the disease

				NOTCH1					SF3B1
		Total patients		Mutated		Wildtype			Mutated		Wildtype
		No	%	No	%	No	%	Sig‐No	No	%	No	%	Sig‐No
Deletion11q22	Positive	7	14	1	14	6	86	1	3	43	4	57	0.095·
	Negative	44	86	7	16	37	84		6	14	38	86
Trisomy12	Positive	28	55	5	18	23	82	0.715	6	21	22	79	0.487
	Negative	23	45	3	13	20	87		3	13	20	87
Deletion13q14,q34	Positive	27	53	5	19	22	81	0.707	2	7	25	93	0.066·
	Negative	24	47	3	13	21	88		7	29	17	71
Deletion17p13	Positive	7	14	3	43	4	57	0.068·	0	0	7	100	0.328
	Negative	44	86	5	11	39	89		9	20	35	80
Dual changes	Positive	13	25	3	23	10	77	0.404	4	31	9	69	0.208
	Negative	38	75	5	13	33	87		5	13	33	87
Complex	Positive	5	10	2	40	3	60	0.17	0	0	5	100	0.571
	Negative	46	90	6	13	40	87		9	20	37	80
Karyotype abnormality	Present	14	70	1	7	13	93	0.521	2	14	12	86	0.549
	Absent	6	30	1	17	5	83		2	33	4	67
Stimulation efficiency grade	2	6	30	1	17	5	83	0.3	2	33	4	67	0.508
	3	10	50	0	0	10	100		1	10	9	90
	4	4	20	1	25	3	75		1	25	3	75
Proliferation grade	3	2	10	0	0	2	100	1	1	50	1	50	0.368
	4	18	90	2	11	16	89		3	17	15	83
Banding grade	3	2	10	0	0	2	100	1	0	0	2	100	1
	4	18	90	2	11	16	89		4	22	14	78
Staging genetic and prognostic immunophenotyping marker	A	15	29	0	0	15	100	0.015·	0	0	15	100	0.008··
	B	9	18	0	0	9	100		0	0	9	100
	C	27	53	8	30	19	70		9	33	18	67

Abbreviations: TS(·), tendency to significant; S(··), significant.